​

Prime Medicine (PRME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PRME Stock Forecast

Prime Medicine (PRME) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $17.25, with a high of $23.00 and a low of $12.00. This represents a 1081.51% increase from the last price of $1.46.

- $5 $10 $15 $20 $25 High: $23 Avg: $17.25 Low: $12 Last Closed Price: $1.46

PRME Stock Rating

Prime Medicine stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 3 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 3 5 Strong Sell Sell Hold Buy Strong Buy

PRME Price Target Upside V Benchmarks

TypeNameUpside
StockPrime Medicine1081.51%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.46$1.46$1.46
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25264--12
May, 25471--12
Apr, 25471--12
Mar, 25471--12
Feb, 25471--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Maury RaycroftJefferies$15.00$5.40177.78%927.40%
Apr 02, 2024David NierengartenWedbush$12.00$6.3289.87%721.92%
Oct 09, 2023Kostas BiliourisBMO Capital$19.00$8.75117.14%1201.37%
Nov 14, 2022Morgan Stanley$23.00$21.128.90%1475.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 26, 2025CitigroupOutperformNeutraldowngrade
May 20, 2025H.C. WainwrightBuyNeutraldowngrade
May 20, 2025CitigroupOutperformOutperformhold
Oct 01, 2024BMO CapitalOutperformOutperformhold
May 20, 2024H.C. WainwrightBuyinitialise
May 15, 2024CitigroupBuyupgrade
Apr 08, 2024Cowen & Co.Buyinitialise
Apr 03, 2024WedbushBuyOutperforminitialise
Apr 02, 2024WedbushBuyinitialise
Nov 14, 2022Morgan StanleyEqual-Weightinitialise

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.25$-2.18$-1.65----
Avg Forecast$-4.18$-1.90$-1.60$-1.22$-1.11$-1.34$-1.31
High Forecast$0.73$-1.69$-1.32$-0.86$-0.02$-0.57$0.23
Low Forecast$-7.45$-2.01$-1.82$-1.61$-1.72$-1.80$-2.33
Surprise %-70.10%14.74%3.13%----

Revenue Forecast

$0 $13M $26M $39M $52M $65M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$2.98M----
Avg Forecast$4.00M$4.44M$11.55M$18.03M$39.16M$6.52M$16.24M
High Forecast$6.41M$7.12M$27.13M$28.87M$62.72M$6.74M$26.01M
Low Forecast$385.42K$428.24K$5.16M$1.74M$3.77M$6.30M$1.56M
Surprise %---74.17%----

Net Income Forecast

$-700M $-540M $-380M $-220M $-60M $100M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.82M$-198.13M$-195.88M----
Avg Forecast$-380.25M$-168.36M$-142.97M$-112.21M$-78.92M$-107.79M$-118.93M
High Forecast$66.44M$-153.57M$-120.44M$-77.81M$-1.67M$-52.26M$20.78M
Low Forecast$-677.62M$-183.14M$-165.50M$-146.60M$-156.18M$-163.32M$-211.94M
Surprise %-67.96%17.69%37.01%----

PRME Forecast FAQ

Is Prime Medicine stock a buy?

Prime Medicine stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Prime Medicine is a favorable investment for most analysts.

What is Prime Medicine's price target?

Prime Medicine's price target, set by 8 Wall Street analysts, averages $17.25 over the next 12 months. The price target range spans from $12 at the low end to $23 at the high end, suggesting a potential 1081.51% change from the previous closing price of $1.46.

How does Prime Medicine stock forecast compare to its benchmarks?

Prime Medicine's stock forecast shows a 1081.51% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Prime Medicine over the past three months?

  • June 2025: 16.67% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Prime Medicine’s EPS forecast?

Prime Medicine's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.22, marking a -26.06% decrease from the reported $-1.65 in 2024. Estimates for the following years are $-1.11 in 2026, $-1.34 in 2027, and $-1.31 in 2028.

What is Prime Medicine’s revenue forecast?

Prime Medicine's average annual revenue forecast for its fiscal year ending in December 2025 is $18.03M, reflecting a 504.33% increase from the reported $2.98M in 2024. The forecast for 2026 is $39.16M, followed by $6.52M for 2027, and $16.24M for 2028.

What is Prime Medicine’s net income forecast?

Prime Medicine's net income forecast for the fiscal year ending in December 2025 stands at $-112M, representing a -42.72% decrease from the reported $-196M in 2024. Projections indicate $-78.925M in 2026, $-108M in 2027, and $-119M in 2028.